4 Top Dividend Stocks to Buy Now
If you’re looking for steady income, dividend stocks are a…
Sell
28
SDZNY Quote, Financials, Valuation and Earnings
Last price:
$42.65
Seasonality move
:
-5.97%
Day range:
$41.91 - $42.88
52-week range:
$27.79 - $46.80
Dividend yield:
1.16%
P/E ratio:
26.84x
P/S ratio:
1.82x
P/B ratio:
2.19x
Volume:
43.5K
Avg. volume:
35.7K
1-year change:
27.28%
Market cap:
$18.3B
Revenue:
$10B
EPS (TTM):
$1.64
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SDZNY
Sandoz Group AG
|
-- | -- | -- | -- | -- |
|
ACIU
AC Immune SA
|
$820.1K | -$0.21 | -95.08% | -273.39% | $9.83 |
|
ADXN
Addex Therapeutics
|
$177.2K | -- | 2.35% | -- | $30.00 |
|
CRSP
CRISPR Therapeutics AG
|
$7.4M | -$1.20 | -96.15% | -0.36% | $84.08 |
|
MOLN
Molecular Partners AG
|
-- | -$0.45 | -100% | -33.3% | $10.51 |
|
NLSP
NLS Pharmaceutics
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SDZNY
Sandoz Group AG
|
$42.65 | -- | $18.3B | 26.84x | $0.50 | 1.16% | 1.82x |
|
ACIU
AC Immune SA
|
$2.72 | $9.83 | $269.1M | -- | $0.00 | 0% | -- |
|
ADXN
Addex Therapeutics
|
$7.52 | $30.00 | $8M | -- | $0.00 | 0% | 13.89x |
|
CRSP
CRISPR Therapeutics AG
|
$39.69 | $84.08 | $3.4B | -- | $0.00 | 0% | -- |
|
MOLN
Molecular Partners AG
|
$4.98 | $10.51 | $183.6M | -- | $0.00 | 0% | 24.20x |
|
NLSP
NLS Pharmaceutics
|
$2.32 | -- | $8.9M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SDZNY
Sandoz Group AG
|
-- | -0.817 | -- | -- |
|
ACIU
AC Immune SA
|
-- | 5.710 | -- | 1.82x |
|
ADXN
Addex Therapeutics
|
-- | 3.160 | -- | 4.36x |
|
CRSP
CRISPR Therapeutics AG
|
-- | 3.448 | -- | -- |
|
MOLN
Molecular Partners AG
|
-- | 2.282 | -- | 14.08x |
|
NLSP
NLS Pharmaceutics
|
-- | 2.905 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SDZNY
Sandoz Group AG
|
-- | -$3.6M | -- | -- | -13.72% | -- |
|
ACIU
AC Immune SA
|
-- | $8.4M | -28.55% | -28.55% | 21.72% | -$12.8M |
|
ADXN
Addex Therapeutics
|
-- | -$719.5K | 91.08% | 91.08% | -2836.3% | -$713.3K |
|
CRSP
CRISPR Therapeutics AG
|
-$11.2M | -$110.1M | -- | -- | -- | -$107.1M |
|
MOLN
Molecular Partners AG
|
-- | -$16.9M | -37.36% | -37.36% | -2407.93% | -$17.3M |
|
NLSP
NLS Pharmaceutics
|
-- | -- | -- | -- | -- | -- |
Sandoz Group AG vs. Competitors
-
Which has Higher Returns SDZNY or ACIU?
AC Immune SA has a net margin of -39.83% compared to Sandoz Group AG's net margin of 21.59%. Sandoz Group AG's return on equity of -- beat AC Immune SA's return on equity of -28.55%.
Company Gross Margin Earnings Per Share Invested Capital SDZNYSandoz Group AG-- -$0.28 -- ACIUAC Immune SA-- $0.06 $154.7M -
What do Analysts Say About SDZNY or ACIU?
Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand AC Immune SA has an analysts' consensus of $9.83 which suggests that it could grow by 261.37%. Given that AC Immune SA has higher upside potential than Sandoz Group AG, analysts believe AC Immune SA is more attractive than Sandoz Group AG.
Company Buy Ratings Hold Ratings Sell Ratings SDZNYSandoz Group AG0 0 0 ACIUAC Immune SA3 0 0 -
Is SDZNY or ACIU More Risky?
Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.294, suggesting its more volatile than the S&P 500 by 29.428%.
-
Which is a Better Dividend Stock SDZNY or ACIU?
Sandoz Group AG has a quarterly dividend of $0.50 per share corresponding to a yield of 1.16%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sandoz Group AG pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SDZNY or ACIU?
Sandoz Group AG quarterly revenues are $74.4M, which are larger than AC Immune SA quarterly revenues of $29.5M. Sandoz Group AG's net income of -$29.6M is lower than AC Immune SA's net income of $6.4M. Notably, Sandoz Group AG's price-to-earnings ratio is 26.84x while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 1.82x versus -- for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SDZNYSandoz Group AG1.82x 26.84x $74.4M -$29.6M ACIUAC Immune SA-- -- $29.5M $6.4M
-
Which has Higher Returns SDZNY or ADXN?
Addex Therapeutics has a net margin of -39.83% compared to Sandoz Group AG's net margin of -2841.85%. Sandoz Group AG's return on equity of -- beat Addex Therapeutics's return on equity of 91.08%.
Company Gross Margin Earnings Per Share Invested Capital SDZNYSandoz Group AG-- -$0.28 -- ADXNAddex Therapeutics-- -$2.78 $13.1M -
What do Analysts Say About SDZNY or ADXN?
Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 298.94%. Given that Addex Therapeutics has higher upside potential than Sandoz Group AG, analysts believe Addex Therapeutics is more attractive than Sandoz Group AG.
Company Buy Ratings Hold Ratings Sell Ratings SDZNYSandoz Group AG0 0 0 ADXNAddex Therapeutics0 0 0 -
Is SDZNY or ADXN More Risky?
Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SDZNY or ADXN?
Sandoz Group AG has a quarterly dividend of $0.50 per share corresponding to a yield of 1.16%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sandoz Group AG pays -- of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SDZNY or ADXN?
Sandoz Group AG quarterly revenues are $74.4M, which are larger than Addex Therapeutics quarterly revenues of $62.3K. Sandoz Group AG's net income of -$29.6M is lower than Addex Therapeutics's net income of -$1.8M. Notably, Sandoz Group AG's price-to-earnings ratio is 26.84x while Addex Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 1.82x versus 13.89x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SDZNYSandoz Group AG1.82x 26.84x $74.4M -$29.6M ADXNAddex Therapeutics13.89x -- $62.3K -$1.8M
-
Which has Higher Returns SDZNY or CRSP?
CRISPR Therapeutics AG has a net margin of -39.83% compared to Sandoz Group AG's net margin of --. Sandoz Group AG's return on equity of -- beat CRISPR Therapeutics AG's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SDZNYSandoz Group AG-- -$0.28 -- CRSPCRISPR Therapeutics AG-- -$1.01 -- -
What do Analysts Say About SDZNY or CRSP?
Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $84.08 which suggests that it could grow by 111.85%. Given that CRISPR Therapeutics AG has higher upside potential than Sandoz Group AG, analysts believe CRISPR Therapeutics AG is more attractive than Sandoz Group AG.
Company Buy Ratings Hold Ratings Sell Ratings SDZNYSandoz Group AG0 0 0 CRSPCRISPR Therapeutics AG11 11 2 -
Is SDZNY or CRSP More Risky?
Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.681, suggesting its more volatile than the S&P 500 by 68.115%.
-
Which is a Better Dividend Stock SDZNY or CRSP?
Sandoz Group AG has a quarterly dividend of $0.50 per share corresponding to a yield of 1.16%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sandoz Group AG pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SDZNY or CRSP?
Sandoz Group AG quarterly revenues are $74.4M, which are larger than CRISPR Therapeutics AG quarterly revenues of --. Sandoz Group AG's net income of -$29.6M is higher than CRISPR Therapeutics AG's net income of -$85.9M. Notably, Sandoz Group AG's price-to-earnings ratio is 26.84x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 1.82x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SDZNYSandoz Group AG1.82x 26.84x $74.4M -$29.6M CRSPCRISPR Therapeutics AG-- -- -- -$85.9M
-
Which has Higher Returns SDZNY or MOLN?
Molecular Partners AG has a net margin of -39.83% compared to Sandoz Group AG's net margin of -2408.81%. Sandoz Group AG's return on equity of -- beat Molecular Partners AG's return on equity of -37.36%.
Company Gross Margin Earnings Per Share Invested Capital SDZNYSandoz Group AG-- -$0.28 -- MOLNMolecular Partners AG-- -$0.57 $165M -
What do Analysts Say About SDZNY or MOLN?
Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Molecular Partners AG has an analysts' consensus of $10.51 which suggests that it could grow by 110.96%. Given that Molecular Partners AG has higher upside potential than Sandoz Group AG, analysts believe Molecular Partners AG is more attractive than Sandoz Group AG.
Company Buy Ratings Hold Ratings Sell Ratings SDZNYSandoz Group AG0 0 0 MOLNMolecular Partners AG2 1 0 -
Is SDZNY or MOLN More Risky?
Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Molecular Partners AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SDZNY or MOLN?
Sandoz Group AG has a quarterly dividend of $0.50 per share corresponding to a yield of 1.16%. Molecular Partners AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sandoz Group AG pays -- of its earnings as a dividend. Molecular Partners AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SDZNY or MOLN?
Sandoz Group AG quarterly revenues are $74.4M, which are larger than Molecular Partners AG quarterly revenues of $787.5K. Sandoz Group AG's net income of -$29.6M is lower than Molecular Partners AG's net income of -$19M. Notably, Sandoz Group AG's price-to-earnings ratio is 26.84x while Molecular Partners AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 1.82x versus 24.20x for Molecular Partners AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SDZNYSandoz Group AG1.82x 26.84x $74.4M -$29.6M MOLNMolecular Partners AG24.20x -- $787.5K -$19M
-
Which has Higher Returns SDZNY or NLSP?
NLS Pharmaceutics has a net margin of -39.83% compared to Sandoz Group AG's net margin of --. Sandoz Group AG's return on equity of -- beat NLS Pharmaceutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SDZNYSandoz Group AG-- -$0.28 -- NLSPNLS Pharmaceutics-- -- -- -
What do Analysts Say About SDZNY or NLSP?
Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 10244.83%. Given that NLS Pharmaceutics has higher upside potential than Sandoz Group AG, analysts believe NLS Pharmaceutics is more attractive than Sandoz Group AG.
Company Buy Ratings Hold Ratings Sell Ratings SDZNYSandoz Group AG0 0 0 NLSPNLS Pharmaceutics0 0 0 -
Is SDZNY or NLSP More Risky?
Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SDZNY or NLSP?
Sandoz Group AG has a quarterly dividend of $0.50 per share corresponding to a yield of 1.16%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sandoz Group AG pays -- of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SDZNY or NLSP?
Sandoz Group AG quarterly revenues are $74.4M, which are larger than NLS Pharmaceutics quarterly revenues of --. Sandoz Group AG's net income of -$29.6M is higher than NLS Pharmaceutics's net income of --. Notably, Sandoz Group AG's price-to-earnings ratio is 26.84x while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 1.82x versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SDZNYSandoz Group AG1.82x 26.84x $74.4M -$29.6M NLSPNLS Pharmaceutics-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Uber Stock Recover?
Shares of Uber Technologies (NYSE:UBER) have had a rough few…
Is ARK Next Generation Internet ETF a Good Investment?
The ARK Next Generation Internet ETF looks like a pretty…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 114x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 11
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
1
MCY alert for Jan 11
Mercury General [MCY] is down 19.87% over the past day.
Buy
84
ATZAF alert for Jan 11
Aritzia [ATZAF] is up 17.63% over the past day.
